Showing 2591-2600 of 5956 results for "".
- Quantel Medical Launches Website Dedicated to Laser Therapies for Retinal Disordershttps://modernod.com/news/quantel-medical-launches-website-dedicated-to-laser-therapies-for-retinal-disorders/2480357/Quantel Medical announced its new website, www.subliminal-laser-therapy.com, dedicated to laser therapies for retinal disorders. "Over the years, the development and introduction of new and innovative laser technologies has
- Amidst the COVID-19 Pandemic, Early Intervention Remains an Obstacle for Overall Eye Health Despite Fear of Blindnesshttps://modernod.com/news/amidst-the-covid-19-pandemic-early-intervention-remains-an-obstacle-for-overall-eye-health-despite-fear-of-blindness/2480352/Globally, most adults, 70 percent, don’t plan to get their eyes examined this year, despite acknowledging the critical importance of eye health. These new findings come from a comprehensive, large-scale Johnson & Johnson Vision Global Eye Health Survey announced in advance of World Sigh
- Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of Iluvien to Significantly Reduce Treatment Burden in Patients with DMEhttps://modernod.com/news/recent-24-month-real-world-paladin-data-demonstrate-the-ability-of-iluvien-to-significantly-reduce-treatment-burden-in-patients-with-dme/2480348/Alimera Sciences announced a data presentation at the American Society of Retina Specialists (ASRS) demonstrating significant reductions in treatment burden in patients receiving Iluvien for diabetic macular edema (DME). The real-world data from the phase 4 PALADIN study
- Ocular Therapeutix Gains New Indication for Dextenza to Include Treatment of Ocular Itching Associated with Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-nabs-new-indication-for-dextenza-to-include-treatment-of-ocular-itching-associated-with-allergic-conjunctivitis/2480340/Ocular Therapeutix announced the FDA has approved its supplemental new drug application (sNDA) to broaden the Dextenza label to add an additional indication for the treatment of ocular itching associated with allergic conjunctivitis. With the approval, Dextenza is the first, FDA-approve
- iCare USA Receives FDA 510(k) Clearance for Eidon Ultra-Widefield Lens Modulehttps://modernod.com/news/icare-usa-presents-ultra-widefield-imaging-for-the-eidon-diagnostics-platform/2480330/iCare USA has received FDA 510 (k) clearance for the Eidon Ultra-Widefield Lens module.&
- CooperVision: SightGlass Vision Diffusion Optics Technology Demonstrates Significant Reduction in Myopia Progression After 2 Yearshttps://modernod.com/news/coopervision-sightglass-vision-diffusion-optics-technology-demonstrates-significant-reduction-in-myopia-progression-after-two-years/2480328/CooperVision’s SightGlass Vision Business has revealed 2-year clinical study data for its Diffusion Optics Technology, which is designed to slow the progression of myopia in children.1 After 2 years, children who wore their Diffusion Optics Technology-enabled spectacles full
- Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studieshttps://modernod.com/news/apellis-announces-detailed-results-from-phase-3-derby-and-oaks-studies-presented-at-retina-society-annual-meeting/2480313/Apellis Pharmaceuticals announced that detailed data from the phase 3 DERBY and OAKS studies were presented for the first time as part of two oral presentations at the Retina Society Annual Scientific Meeting in Chicago.The studies evaluated the efficacy and safety of pegcetacoplan, an investigat
- TissueTech Hosts Inaugural Leadership Summit to Discuss Best Practices on Regenerative Medicinehttps://modernod.com/news/tissuetech-hosts-inaugural-leadership-summit-to-discuss-best-practices-on-regenerative-medicine/2480288/TissueTech announced that the company had completed its first physician leadership summit, Beyond the Horizon 2021,
- Comorbid Ophthalmic, Systemic Conditions Linked With Higher Risk of Dementiahttps://modernod.com/news/comorbid-ophthalmic-systemic-conditions-linked-with-higher-risk-of-dementia/2480281/People with both ophthalmic and systemic conditions were found to be at higher risk of dementia compared with those with only 1 such condition, according to a report in the American Journal of Managed Care. Some ophthalmic condition
- MeiraGTx Announces Data at EURETINA 2021 Demonstrating Reversal of Disease Progression Following Treatment With AAV5-RPGR in XLRPhttps://modernod.com/news/meiragtx-announces-data-at-euretina-2021-demonstrating-reversal-of-disease-progression-following-treatment-with-aav5-rpgr-in-xlrp/2479499/MeiraGTx Holdings announced new data from subjects treated in the phase 1/2 dose escalation phase of Study MGT009 indicating AAV5-RPGR, an investigational gene therapy in development for the treatment of X-linked retinitis pigmentosa (XLRP), reverses course of disease progression when retinal fun